Whither Screening for Lung Cancer? | Zendy

J C Ruckdeschel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Whither Screening for Lung Cancer?

Author(s) -

J C Ruckdeschel

Publication year - 1988

Publication title -

jnci journal of the national cancer institute

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.797

H-Index - 356

eISSN - 1460-2105

pISSN - 0027-8874

DOI - 10.1093/jnci/80.2.78

Subject(s) - lung cancer , medicine , lung cancer screening

1. ZACHARSKJ LR, HENDERSON WG, RICKLES FR, et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 1981245:831-835. 2. PEREZ CA. Non-small cell carcinoma of the lung: dose-time parameters. Cancer Treat Symp 1985^:131-142. 3. LICHTNER RB, GALLICK GE, NICOLSON GL. The pyrimido-pyrimidine analog RA-233 can modify the expression of p21"" protein and the growth promoting activity of EGF on some cloned 13762 NF metastatic rat mammary adenocarcinoma cells. Proc ASCO 1986,27:213. 4. RODENHUIS S, VAN DE WETERING ML, Mooi WJ, et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987;317:929-935. 5. LEE 1, RADOSEVICH J, CARNEY W, et al. Immunohistochemical detection of unaltered and mutated ras oncogene products in pulmonary neoplasms. Lab Invest 1987^6:42A.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research